Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385422182> ?p ?o ?g. }
- W4385422182 endingPage "3859" @default.
- W4385422182 startingPage "3859" @default.
- W4385422182 abstract "Bruton tyrosine kinase inhibitors (BTKi) and the BCL2 inhibitor venetoclax, with or without the anti-CD20 monoclonal antibody Obinutuzumab, represent the preferred options for the first-line therapy of CLL because they are more effective and may improve quality of life. However, patient inclusion criteria are heterogeneous across trials designed for older patients, and the identification of CLL-specific parameters identifying unfit patients at risk of developing drug-specific adverse events is required to guide treatment choice. Due to inclusion/exclusion criteria in trials, higher discontinuation rates with BTKi were reported in real-world studies, and registry analyses provided useful information on factors predicting earlier discontinuation in a real-world setting. Though targeted agents were shown to be cost-effective treatments in high-income countries, the out-of-pocket expenses may limit accessibility to these drugs, and the overall expenditure for new drugs in CLL is projected to increase substantially, posing an issue for sustainability. This being said, the choice of a finite-duration treatment based on venetoclax-containing regimens or treatment until progression with BTKi is today possible in high-income countries, and the therapy choice drivers are represented by coexisting medical conditions rather than age, patient expectations, logistics, and sustainability." @default.
- W4385422182 created "2023-08-01" @default.
- W4385422182 creator A5025460426 @default.
- W4385422182 creator A5026992937 @default.
- W4385422182 creator A5062047451 @default.
- W4385422182 creator A5062236077 @default.
- W4385422182 creator A5069068528 @default.
- W4385422182 creator A5081899947 @default.
- W4385422182 creator A5088718014 @default.
- W4385422182 date "2023-07-29" @default.
- W4385422182 modified "2023-09-26" @default.
- W4385422182 title "First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era" @default.
- W4385422182 cites W1196637763 @default.
- W4385422182 cites W1644085412 @default.
- W4385422182 cites W1747288778 @default.
- W4385422182 cites W1971980459 @default.
- W4385422182 cites W2000445173 @default.
- W4385422182 cites W2018713883 @default.
- W4385422182 cites W2025271171 @default.
- W4385422182 cites W2047982141 @default.
- W4385422182 cites W2055804644 @default.
- W4385422182 cites W2076072081 @default.
- W4385422182 cites W2099847305 @default.
- W4385422182 cites W2108206643 @default.
- W4385422182 cites W2116963499 @default.
- W4385422182 cites W2120319857 @default.
- W4385422182 cites W2136067770 @default.
- W4385422182 cites W2140606816 @default.
- W4385422182 cites W2144617723 @default.
- W4385422182 cites W2161374186 @default.
- W4385422182 cites W2192121806 @default.
- W4385422182 cites W2233614027 @default.
- W4385422182 cites W2295348655 @default.
- W4385422182 cites W2296618733 @default.
- W4385422182 cites W2369297677 @default.
- W4385422182 cites W2480110608 @default.
- W4385422182 cites W2519500141 @default.
- W4385422182 cites W2553911513 @default.
- W4385422182 cites W2557801192 @default.
- W4385422182 cites W2558394416 @default.
- W4385422182 cites W2580821712 @default.
- W4385422182 cites W2607604861 @default.
- W4385422182 cites W2622422839 @default.
- W4385422182 cites W2742159800 @default.
- W4385422182 cites W2765156323 @default.
- W4385422182 cites W2777747661 @default.
- W4385422182 cites W2792666902 @default.
- W4385422182 cites W2800186514 @default.
- W4385422182 cites W2803967243 @default.
- W4385422182 cites W2806627663 @default.
- W4385422182 cites W2892153379 @default.
- W4385422182 cites W2902089967 @default.
- W4385422182 cites W2902484351 @default.
- W4385422182 cites W2902706178 @default.
- W4385422182 cites W2923415241 @default.
- W4385422182 cites W2946882253 @default.
- W4385422182 cites W2947924227 @default.
- W4385422182 cites W2948436219 @default.
- W4385422182 cites W2972517288 @default.
- W4385422182 cites W2979861582 @default.
- W4385422182 cites W2992505147 @default.
- W4385422182 cites W3016538158 @default.
- W4385422182 cites W3021316203 @default.
- W4385422182 cites W3021713242 @default.
- W4385422182 cites W3036418726 @default.
- W4385422182 cites W3087815436 @default.
- W4385422182 cites W3092937247 @default.
- W4385422182 cites W3094712772 @default.
- W4385422182 cites W3096800474 @default.
- W4385422182 cites W3132537256 @default.
- W4385422182 cites W3133480426 @default.
- W4385422182 cites W3137807598 @default.
- W4385422182 cites W3165432856 @default.
- W4385422182 cites W3174190143 @default.
- W4385422182 cites W3183349190 @default.
- W4385422182 cites W3185756680 @default.
- W4385422182 cites W3186824000 @default.
- W4385422182 cites W3195353771 @default.
- W4385422182 cites W3203683811 @default.
- W4385422182 cites W3204168645 @default.
- W4385422182 cites W3204288598 @default.
- W4385422182 cites W3208793490 @default.
- W4385422182 cites W3211328341 @default.
- W4385422182 cites W3213933946 @default.
- W4385422182 cites W3216410994 @default.
- W4385422182 cites W4200227573 @default.
- W4385422182 cites W4205825534 @default.
- W4385422182 cites W4205875819 @default.
- W4385422182 cites W4205969691 @default.
- W4385422182 cites W4206417853 @default.
- W4385422182 cites W4213170825 @default.
- W4385422182 cites W4213453359 @default.
- W4385422182 cites W4221002169 @default.
- W4385422182 cites W4223904810 @default.
- W4385422182 cites W4224138250 @default.
- W4385422182 cites W4224210021 @default.
- W4385422182 cites W4224239951 @default.
- W4385422182 cites W4224302256 @default.